Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sequenom Schedules Fourth Quarter and Full Year 2015 Results Conference Call for March 2, 2016

SAN DIEGO, Feb. 24, 2016 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced it will report financial results for the fourth quarter 2015 after closing of the NASDAQ Global Market on Wednesday, March 2, 2016.

SEQUENOM logo.

A conference call hosted by Dr. Dirk van den Boom, President and CEO, and other members of senior management will take place on Wednesday, March 2, 2016, at 5:00 p.m. ET (2:00 p.m. PT) and will be webcast live on the Sequenom Website.

Call participants should dial 877-883-0383 (U.S. / Canada) or 412-902-6506 (other countries). Please use code 9189690. A telephonic replay will be available through April 2, 2016 by dialing 877-344-7529 (US toll free), 855-669-9658 (Canada toll free), or 412-317-0088 (international toll), and entering the conference number 10081831.

The conference call webcast is also accessible through the "Invest" section of the Sequenom Website at www.sequenom.com/invest

About Sequenom  

Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing company dedicated to women's health through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information.  For more information, visit www.sequenom.com.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT21® PLUS, NextView®, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit www.laboratories.sequenom.com and follow @SequenomLabs.

SEQUENOM®, HerediT®, MaterniT® GENOME, MaterniT21® PLUS, NextView®, SensiGene®, VisibiliT™ and Sequenom Laboratories™ are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sequenom-schedules-fourth-quarter-and-full-year-2015-results-conference-call-for-march-2-2016-300225063.html

SOURCE Sequenom, Inc.